Cargando…

A phase I/II study of stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumours (RAPPORT): Clinical trial protocol

BACKGROUND: The management of oligometastatic clear cell renal cell carcinoma (ccRCC) varies widely, ranging from observation to resection or systemic therapies. Prolonged survival has been observed following resection or stereotactic ablative body radiotherapy (SABR). Immunotherapy combinations hav...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pryor, David, Bressel, Mathias, Lawrentschuk, Nathan, Tran, Ben, Mooi, Jennifer, Lewin, Jeremy, Azad, Arun, Colyer, Duncan, Neha, Nitika, Shaw, Mark, Chander, Sarat, Neeson, Paul, Moon, Daniel, Cuff, Katharine, Wood, Simon, Murphy, Declan G., Sandhu, Shahneen, Loi, Sherene, Siva, Shankar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7807247/ https://www.ncbi.nlm.nih.gov/pubmed/33490707 http://dx.doi.org/10.1016/j.conctc.2021.100703

Ejemplares similares

NeoAdjuvant pembrolizumab and STEreotactic radiotherapy prior to nephrectomy for renal cell carcinoma (NAPSTER): A phase II randomised clinical trial
por: Ali, Muhammad, et al.
Publicado: (2023)

Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: A prospective clinical trial
por: David, Steven, et al.
Publicado: (2019)

Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in the Management of Oligometastatic Renal Cell Carcinoma
por: Udovicich, Cristian, et al.
Publicado: (2022)

Stereotactic ablative radiotherapy for oligometastatic prostate cancer
por: Gallizia, Elena, et al.
Publicado: (2022)

P1066: PEMBROLIZUMAB MONOTHERAPY AS A FIRST THERAPY FOR HODGKIN LYMPHOMA IS DELIVERABLE IN OLDER OR ABVD INELIGIBLE PATIENTS, DOES NOT PRECLUDE SUBSEQUENT THERAPY, AND PROVIDES ADEQUATE SURVIVAL.
por: Dickinson, Michael, et al.
Publicado: (2023)

A randomised phase II trial of Stereotactic Ablative Fractionated radiotherapy versus Radiosurgery for Oligometastatic Neoplasia to the lung (TROG 13.01 SAFRON II)
por: Siva, Shankar, et al.
Publicado: (2016)

Stereotactic Body Radiotherapy for Oligometastatic Disease in Non-small Cell Lung Cancer
por: Wujanto, Caryn, et al.
Publicado: (2019)

Stereotactic Ablative Radiotherapy for Oligometastatic Disease in Liver
por: Kim, Myungsoo, et al.
Publicado: (2014)

A Pilot Trial of Pembrolizumab plus Prostatic Cryotherapy for Men with Newly Diagnosed Oligometastatic Hormone-Sensitive Prostate Cancer
por: Ross, Ashley E., et al.
Publicado: (2019)

Safety, Efficacy, and Patterns of Failure After Single-Fraction Stereotactic Body Radiation Therapy (SBRT) for Oligometastases
por: Sogono, Paolo, et al.
Publicado: (2021)

SABR in oligometastatic breast cancer: Current status and future directions
por: Stewart, Rachel, et al.
Publicado: (2021)

Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer
por: Ahmed, Kamran A., et al.
Publicado: (2013)

Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence
por: Decaestecker, Karel, et al.
Publicado: (2014)

Role of Radiosurgery/Stereotactic Radiotherapy in Oligometastatic Disease: Brain Oligometastases
por: Mazzola, Rosario, et al.
Publicado: (2019)

Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Spine Metastases: An Overview
por: Zeng, Kang Liang, et al.
Publicado: (2019)

Extracranial Stereotactic Body Radiotherapy in Oligometastatic or Oligoprogressive Breast Cancer
por: Weykamp, Fabian, et al.
Publicado: (2020)

Stereotactic body radiotherapy for bone oligometastatic disease in prostate cancer
por: Patel, Priyanka H., et al.
Publicado: (2019)

Stereotactic ablative radiotherapy for oligometastatic breast cancer in elderly patients
por: Morales-Orue, Ignacio, et al.
Publicado: (2020)

Outcome of lung oligometastatic patients treated with stereotactic body irradiation
por: Virbel, Guillaume, et al.
Publicado: (2022)

Stereotactic body radiotherapy for recurrent and oligometastatic soft tissue sarcoma
por: Feng, Xiao-Yao, et al.
Publicado: (2022)

Oligometastatic Prostate Cancer
por: Stevens, Daniel J., et al.
Publicado: (2016)

Imaging of Oligometastatic Disease
por: Vietti Violi, Naik, et al.
Publicado: (2022)

Local consolidative therapy for synchronous oligometastatic non‐small cell lung cancer treated with first‐line pembrolizumab: A retrospective observational study
por: Chen, Ya, et al.
Publicado: (2022)

Locoregional control and survival after lymph node SBRT in oligometastatic disease
por: Loi, Mauro, et al.
Publicado: (2018)

Rapport scientifique /
Publicado: (1990)

Rapport 1967
por: European Committee for Future Accelerators. Geneva, et al.
Publicado: (1967)

TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney - FASTRACK II
por: Siva, Shankar, et al.
Publicado: (2018)

NaF PET/CT for response assessment of prostate cancer bone metastases treated with single fraction stereotactic ablative body radiotherapy
por: Hardcastle, Nicholas, et al.
Publicado: (2019)

Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy
por: Loi, Sherene
Publicado: (2013)

Knowing When to Use Stereotactic Ablative Radiation Therapy in Oligometastatic Cancer
por: Franceschini, Davide, et al.
Publicado: (2021)

CyberKnife Stereotactic Ablative Radiotherapy for Recurrent or Oligometastatic Gynecological Cancers
por: Kataria, Tejinder, et al.
Publicado: (2021)

Stereotactic Radiotherapy in the Treatment of Paraneoplastic Vasculitis in Oligometastatic Renal Cell Carcinoma
por: Burgess, Laura, et al.
Publicado: (2021)

Stereotactic radiation therapy for oligometastatic esophagogastric adenocarcinoma: outcome and prognostic factors
por: Franceschini, Davide, et al.
Publicado: (2023)

Combining Radiotherapy and Immunotherapy in Metastatic Breast Cancer: Current Status and Future Directions
por: David, Steven, et al.
Publicado: (2022)

Local ablative therapies in oligometastatic NSCLC-upfront or outback?—a narrative review
por: Tjong, Michael C., et al.
Publicado: (2021)

The biology and treatment of oligometastatic cancer
por: Reyes, Diane K., et al.
Publicado: (2015)

Radiotherapy for Oligometastatic Lung Cancer
por: Bergsma, Derek P., et al.
Publicado: (2017)

Highlights on the Management of Oligometastatic Disease
por: Alshehri, Salem M., et al.
Publicado: (2020)

Rapport ECFA1967
Publicado: (1967)

Rapport ECFA 1967
por: CERN Press Office. Geneva
Publicado: (1967)

Cannot write session to /tmp/vufind_sessions/sess_9cpf3vo1a4v0nmenvstlvs2cjv